Prize4Life announces the launch of the updated $1M ALS Treatment Prize4Life, opening June 6th, 2012.
In October of 2010, Prize4Life closed submissions for the $1M ALS Treatment Prize4Life, which was announced in 2008 and aimed to fill the drug development pipeline with promising therapeutics by encouraging researchers to extend the lives of ALS mouse models by 25%. To date, no compound tested in ALS SOD mouse models under rigorous experimental conditions has demonstrated the ability to extend lifespan in these animals by even 10%. This lack of effect in animals has correlated with a lack of effect in patients and over the past 7 years the ALS community has had to withstand the disappointment of numerous failed clinical trials. While the 25% bar set by Prize4Life was certainly high, this level of efficacy remains the best hope for identifying a new ALS treatment and bringing it to the attention of the drug development community.
During the first round of open competition, the prize recruited 33 teams from both academia and industry and attracted 17 new groups to ALS research and drug development. While it did not lead to the identification of a winning candidate, the prize created momentum for continuation of promising research efforts. We have decided to re-open the competition given the continued need for an effective ALS treatment. The revised criteria take into account changes in the ALS landscape in the ensuing four years since the prize was first launched. We believe there is an opportunity for the launch of the updated $1M ALS Treatment Prize4Life to greatly accelerate research towards finding an effective treatment.
Officially opening on June 6, 2012, the updated $1M ALS Treatment Prize4Life seeks to recruit new minds and ideas to ALS research and encourage the generation of solid preclinical data packages. Through the prize initiative and supportive infrastructure programs, such as The ALS Forum and the Prize4Life SOD1 Mouse Colony, we can infuse necessary innovation into a sluggish drug development pipeline and identify a strong therapeutic candidate worthy of advancing to clinical testing in ALS patients. By incentivizing both new and experienced ALS researchers, and providing them access to critical resources, the $1M ALS Treatment Prize4Life will accelerate the discovery, development, and delivery of treatments for thousands of patients and families desperate for help. View the updated prize criteria.
In December 2013, twenty teams competing for the $1M ALS Treatment Prize4Life competition submitted interim milestone reports. These milestone reports will be reviewed by the Scientific Advisory Board as part of the process of eventually choosing a winning solution to the $1M ALS Treatment Prize4Life competition.
To register for the $1M Treatment Prize competition, contact Dr. Sara Shnider at ALS_Treatment_Prize@prize4life.org.